AU663067B2 - Analogs of acidic fibroblast growth factor having enhanced stability and biological activity - Google Patents
Analogs of acidic fibroblast growth factor having enhanced stability and biological activityInfo
- Publication number
- AU663067B2 AU663067B2 AU91524/91A AU9152491A AU663067B2 AU 663067 B2 AU663067 B2 AU 663067B2 AU 91524/91 A AU91524/91 A AU 91524/91A AU 9152491 A AU9152491 A AU 9152491A AU 663067 B2 AU663067 B2 AU 663067B2
- Authority
- AU
- Australia
- Prior art keywords
- analog
- amino acid
- growth factor
- fibroblast growth
- acidic fibroblast
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 title claims description 23
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 title claims description 21
- 230000004071 biological effect Effects 0.000 title claims description 18
- 235000001014 amino acid Nutrition 0.000 claims description 52
- 150000001413 amino acids Chemical class 0.000 claims description 44
- 229940024606 amino acid Drugs 0.000 claims description 42
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 39
- 239000004471 Glycine Substances 0.000 claims description 21
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 11
- 101000846393 Bos taurus Fibroblast growth factor 1 Proteins 0.000 claims description 11
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 11
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 11
- 235000009582 asparagine Nutrition 0.000 claims description 11
- 229960001230 asparagine Drugs 0.000 claims description 11
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 11
- 235000002374 tyrosine Nutrition 0.000 claims description 11
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 11
- 125000000539 amino acid group Chemical group 0.000 claims description 10
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 9
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 9
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 9
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 9
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 9
- 235000003704 aspartic acid Nutrition 0.000 claims description 9
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 9
- 235000013930 proline Nutrition 0.000 claims description 9
- 235000004400 serine Nutrition 0.000 claims description 9
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 6
- 235000013922 glutamic acid Nutrition 0.000 claims description 6
- 239000004220 glutamic acid Substances 0.000 claims description 6
- 101000846416 Homo sapiens Fibroblast growth factor 1 Proteins 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 4
- 239000004473 Threonine Substances 0.000 claims description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 4
- 235000004554 glutamine Nutrition 0.000 claims description 4
- 235000008521 threonine Nutrition 0.000 claims description 4
- 239000004475 Arginine Substances 0.000 claims description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 3
- 239000004472 Lysine Substances 0.000 claims description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 3
- 235000009697 arginine Nutrition 0.000 claims description 3
- 235000018977 lysine Nutrition 0.000 claims description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 3
- 235000008729 phenylalanine Nutrition 0.000 claims description 3
- 230000007935 neutral effect Effects 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 1
- -1 seririe Chemical compound 0.000 claims 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 60
- 241000283690 Bos taurus Species 0.000 description 44
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 42
- 229920000669 heparin Polymers 0.000 description 42
- 229960002897 heparin Drugs 0.000 description 42
- 108090000623 proteins and genes Proteins 0.000 description 38
- 235000018102 proteins Nutrition 0.000 description 31
- 102000004169 proteins and genes Human genes 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 20
- 238000006467 substitution reaction Methods 0.000 description 19
- 125000003275 alpha amino acid group Chemical group 0.000 description 17
- 230000000694 effects Effects 0.000 description 15
- 238000001228 spectrum Methods 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 239000001509 sodium citrate Substances 0.000 description 12
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 12
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 10
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 9
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 9
- 235000011130 ammonium sulphate Nutrition 0.000 description 9
- 230000003389 potentiating effect Effects 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 8
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 8
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 8
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 7
- 230000002297 mitogenic effect Effects 0.000 description 7
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 206010052428 Wound Diseases 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- 230000035876 healing Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 108020004705 Codon Proteins 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- 238000004925 denaturation Methods 0.000 description 4
- 230000036425 denaturation Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 101100067721 Caenorhabditis elegans gly-3 gene Proteins 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 238000002983 circular dichroism Methods 0.000 description 3
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 238000012935 Averaging Methods 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 2
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 2
- 101001052035 Homo sapiens Fibroblast growth factor 2 Proteins 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000002491 angiogenic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000001142 circular dichroism spectrum Methods 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 238000002050 diffraction method Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000001641 gel filtration chromatography Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000219 mutagenic Toxicity 0.000 description 2
- 230000003505 mutagenic effect Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000010512 thermal transition Effects 0.000 description 2
- 230000008467 tissue growth Effects 0.000 description 2
- 229960004441 tyrosine Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000002424 x-ray crystallography Methods 0.000 description 2
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 241001274237 Caranx latus Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102100025691 Dapper homolog 1 Human genes 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 241000720950 Gluta Species 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 101000856043 Homo sapiens Dapper homolog 1 Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229940064551 bovine heparin Drugs 0.000 description 1
- WUKWITHWXAAZEY-UHFFFAOYSA-L calcium difluoride Chemical compound [F-].[F-].[Ca+2] WUKWITHWXAAZEY-UHFFFAOYSA-L 0.000 description 1
- 229910001634 calcium fluoride Inorganic materials 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000004295 hippocampal neuron Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002241 neurite Anatomy 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- ASHGTUMKRVIOLH-UHFFFAOYSA-L potassium;sodium;hydrogen phosphate Chemical compound [Na+].[K+].OP([O-])([O-])=O ASHGTUMKRVIOLH-UHFFFAOYSA-L 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 150000003355 serines Chemical class 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
- C07K14/501—Fibroblast growth factor [FGF] acidic FGF [aFGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
ANALOGS OF ACIDIC FIBROBLAST GROWTH FACTOR HAVING ENHANCED STABILITY AND BIOLOGICAL ACTIVITY
Background
The complex process of healing which follows injury to tissue, such as by wounding or burning, is mediated by a number of protein factors, sometimes referred to as soft tissue growth factors. These factors are required for the growth and differentiation of new cells to replace the destroyed tissue. Included within this group of soft tissue growth factors is a protein family of fibroblast growth factors (FGFs) . The FGFs are mitogenic and chemotactic for a variety of cells of epithelial, mesenchymal, and neural origins. In addition, FGFs are angiogenic, that is they are able to stimulate the formation of blood vessels.
Acidic FGF (aFGF) and basic FGF (bFGF) are considered to be two "original" members of the FGF family. Both aFGF and bFGF are believed to be derived from the same ancestral gene, with both molecules having approximately 55% sequence identity in addition to the same intron/exon structure. Acidic FGF and bFGF are also known to bind to the same receptor, although the existence of specific aFGF and bFGF receptors has not been ruled out. Several molecular weight forms of aFGF and bFGF are found in different tissues. However, Southern blotting experiments suggest that there is only one gene each for aFGF and bFGF, with differences between these molecules probably being due to post- translational processing. Both acidic and basic FGF are mitogens for a wide variety of cell types of mesodermal and neuroectoder al origin, and are able to induce angiogenesis both in vitro and in vivo . See, e.g.,
Gospodarowicz et al, Exp. Eye Res. , 28, 501-514 (1979). The range of biological activities of the two classes is nearly identical, although bFGF is about ten times more potent than aFGF in most bioassay systems.
A shared distinguishing feature of aFGF and bFGF is the propensity of these factors to bind tightly to heparin. The affinity of aFGF for heparin appears to be weaker than for bFGF, with aFGF having an anionic isoelectric point. Thomas et al, Proc. Nat . Acad. Sci . USA, 82, 6409-6413 (1984) . The unique heparin binding property of aFGF and bFGF has greatly facilitated purification of these factors.
The discovery that FGFs have strong affinity for immobilized heparin has also spurred investigation into the regulatory role of heparin-like molecules in the in vivo biology of FGFs. Although the f ll spectrum of functions for heparin has yet to be determined, it is known that heparin can regulate FGF function in several ways. Lobb, Eur. J. Clin . Invest . , 18, 321-326 (1988). For example, heparin-like molecules can play a direct role in FGF function, including the activation, or potentiation, of aFGFs. ϋhlrich et al, Biochem. Biophys . Res . Comm. , 137, 1205-1213 (1986) .
There is, however, no direct correlation between the affinity of the FGF for immobilized heparin and its ability to be potentiated by soluble heparin. In this respect, the potentiating power of heparin appears to be selective for aFGF. For example, Uhlrich et al, ibid, found the degree of potentiation of pure aFGF to be about ten times greater than that of pure bFGF, raising the potency of the aFGF to approximately the same level as that of bFGF. However, in the presence of fetal calf
serum, the potentiating effect of heparin was found to decrease significantly. Uhlrich et al, ibid.
The use of FGF proteins is believed to be effective in promoting the healing of tissue subjected to trauma. The unique angiogenic property of FGFs makes these factors especially valuable in the healing of deep wounds. The bFGF native proteins have been alleged to be useful in the treatment of myocardial infarction. U.S. Patents No. 4,296,100 and 4,378,347. In addition, human bFGF has been found to increase neuronal survival and neurite extension in fetal rat hippocampal neurons, suggesting that this factor may also be useful in the treatment of degenerative neurological disorders, such as Alzheimer's disease and Parkinson's disease.
Wallicke et al, Proc. Natl . Acad. Sci . USA, 83, 3012- 3016 (1986) .
A major stumbling block to the effective use of aFGF in therapeutic applications appears to be related to its significantly lower biological activity, as compared with bFGF. Although studies with heparin suggest that the observed difference in potency between aFGF and bFGF can be substantially diminished by using heparin to boost the activity of aFGF to a level comparable to that of bFGF, the use of heparin in pharmaceutical preparations may not always be desirable. In this regard, it is important to note that heparin, a highly sulphated glycosaminoglycan of heterogeneous structure, is known to be an anticoagulant which functions by accelerating the rate at which antithrombin III inactivates the proteases of homeostasis. Jacques, Pharmacol Rev, 31, 99-166 (1980) . It is not known whether it might be deleterious to use heparin in a pharmaceutical preparation for the treatment of deep
wounds, where some degree of coagulation may be desired to achieve proper healing.
In addition, practical considerations can be expected to arise where heparin is incorporated into a pharmaceutical preparation for wound healing. Drug delivery concerns include the matter of controlling the composition of the pharmaceutical preparation (containing the combination of aFGF and heparin) upon entry into the patient's body. Moreover, the negative effect of fetal calf serum on the potentiating effect of heparin on aFGF, observed by Uhlrich et al, suggest that any advantage obtained by including heparin in the pharmaceutical preparation as an activating or potentiating factor for aFGF could be completely negated or lost once it made contact with the patient's own serum.
It is an object of the present invention to provide an analog of aFGF which exhibits enhanced stability and biological activity in the absence of heparin. It is a further object of the present invention to provide an aFGF analog for therapeutic use.
Suiτwar of e inven ion
The present invention provides novel analogs of aFGF which are more stable and exhibit greater biological activity in the absence of heparin than naturally occurring aFGF. Enhanced stability is achieved by substituting at least one amino acid having higher loop-forming potential for an amino acid residue of lower loop-forming potential in the naturally occurring aFGF molecule in the area of about amino acids 90 to 97. A preferred analog of the present invention
incorporates the substitution of an amino acid having higher loop-forming potential for the histidine residue at amino acid position 93 in naturally occurring aFGF.
Brief Description of the Drawings
FIG. 1 shows the nucleic acid and amino acid sequences of recombinant bovine [Ala47,Gly93] aFGF.
FIG. 2 shows the amino acid sequence of recombinant human [Alal6,Gly93] aFGF.
FIG. 3 demonstrates the elution profiles for bovine [Ala-47] and [Ala47fGly93] aFGF analogs using hydrophobic interaction chromatography.
FIGS. 4A and 4B shows the circular dichroic spectra for bovine [Ala^7] and [Ala47,ciy93] aFGF analogs.
FIG. 5 shows the second derivative FTIR spectra of bovine [Ala*47] and [Ala47,Gly93] aFGF analogs in the amide I* (C=0 stretch in deuterated proteins) region.
FIG. 6 is a graph showing a plot of the log of the concentration of bovine [Ala*47] and [Ala*47,Gly93] aFGF analogs and human [Ser70,ser88] bFGF versus the percentage of maximal stimulation.
FIG. 7 is a graph showing the loss of activity over time of bovine [Ala47] and [Ala47,Gly93] aFGF analogs in the absence of heparin as compared with human [Ser70,ser88] bFGF.
FIG. 8 shows the structure of the bovine [Ala*47fGly93] aFGF analog of the present invention, as determined by X-ray crystallography.
Detailed Description of the Invention
Novel analogs of aFGF are provided in accordance with the present invention. These analogs exhibit improved stability and enhanced biological activity, as compared with naturally occurring aFGF, in the absence of heparin. The aFGF analogs of the present invention have at least one different amino acid residue from naturally occurring aFGF in the area of about amino acid residues 90 to 97 (based on the numbering of the known amino acid sequence for bovine aFGF, as shown in
Fig. 1) . The different amino acid(s) is selected for its higher loop-forming potential in order to stabilize this area of the aFGF molecule. Amino acids having relatively high loop-forming potential include glycine, proline, tyrosine, aspartic acid, asparagine, and serine. Leszcynski et al, Science, 234, 849-855 (1986) (relative values of loop-forming potential assigned on the basis of frequency of appearance in loop structures of naturally occurring molecules) . Preferably, a different amino acid having higher loop-forming potential replaces the histidine residue at amino acid position 93 of naturally occurring aFGF. Still more preferably, the histidine residue at amino acid position 93 is replaced with a glycine residue.
Other additions, substitutions, and/or deletions may be made to the aFGF analog of the present invention. For example, the aFGF analog may also optionally include an amino acid substitution for non-conserved cysteine residues (i.e., the cysteine residue at position 47 of
the bovine aFGF molecule and the cysteine residue at position 16 of the human aFGF molecule) . In addition, the aFGF analogs of the present invention which are expressed from E. coli host cells may include an initial methionine amino acid residue (i.e., at position -1, as shown in Fig. 1) . Alternatively, one or more of the terminal amino acid residues may be deleted from the DNA sequence, as is known to those skilled in the art, while substantially retaining the enhanced biological activity of the aFGF analog.
DNA sequences coding for all or part of aFGF analogs are also provided according to the present invention. Such sequences preferably may include the incorporation of codons "preferred" for expression by selected E. coli host strains ("_7. coli expression codons") , the provision of sites of cleavage by restriction endonuclease enzymes, and/or the provision of additional initial, terminal, or intermediate DNA sequences which facilitate construction of readily expressed vectors. These novel DNA sequences include sequences useful in securing the expression of the aFGF analogs of the present invention in both eucaryotic and procaryotic host cells, such as E. coli .
More specifically, the DNA sequences of the present invention may comprise the DNA sequence set forth in Fig. 1, wherein at least one codon encoding an amino acid residue in the area of about amino acids 90 to 97 is replaced by a codon encoding a different amino acid residue having a higher loop-forming potential (hereinafter "analog sequence(s) ") , as well as a DNA sequence which hybridizes to one of the analog sequences or to fragments thereof, and, a DNA sequence which, but
for the degeneracy of the genetic code, would hybridize to one of the analog sequences.
The aFGF analogs of the present invention can be encoded, expressed, and purified by any one of a number of recombinant technology methods known to those skilled in the art. The preferred production method will vary depending upon many factors and considerations, including the cost and availability of materials and other economic considerations. The optimum production procedure for a given situation will be apparent to those skilled in the art through minimal experimentation. The analogs of the present invention can be expressed at particularly high levels using E. coli host cells, with the resulting expression product being subsequently purified to near homogeneity using procedures known in the art. A typical purification procedure involves first solubilizing the inclusion bodies containing the aFGF analogs, followed by ion exchange chromatography, then refolding of the protein, and, finally, hydrophobic interaction chromatography.
The aFGF analogs of the present invention exhibit a surprising degree of enhanced biological activity in the absence of heparin. While it is known that more stable bFGF analogs can be obtained through the substitution of serine or other neutral amino acids in place of certain cysteine residues (for example, as disclosed in published PCT Patent Application No. 88/04189), substitution for the non-conserved cysteine residue at position 47 of naturally occurring bovine aFGF alone is not believed to be significant in enhancing the biological activity and/or stability of an aFGF analog. This is demonstrated by the lower activity exhibited by
a bovine [Ala47] aFGF analog (cysteine substituted) compared with a bovine [Ala47,Gly93] aFGF analog (having the desired amino acid substitution in the residue 90 to 97 region of the aFGF molecule) , as set forth in the examples which follow. Specifically, the bovine [Ala*47fGly9 ] analog, although still less potent compared with the bFGF, was found to be approximately ten times more potent than the bovine [Ala47] aFGF analog. Upon the addition of 45 μg/ml heparin, bioactivity of all three forms of FGF was enhanced, with the bovine [Ala47,Gly93] analog, the bovine [Ala47,ciy93] analog, and human [Ser70,Ser88] bFGF analog having substantially identical potency.
The reason for the enhanced mitogenic activity and stability of the bovine [Ala47,Gly93] aFGF analog relative to bovine [Ala47] aFGF in the absence of heparin was not immediately clear. The substitution of glycine for the histidine residue at position 93 appeared to make the aFGF molecule somewhat more hydrophobic, but did not appear to drastically alter its tertiary structure, as determined by circular dichroism and FTIR spectroscop . However, the relative differences in the activities observed in the in vitro bioassays for the bovine [Ala 7,Gly93] aFGF analog and for the bovine [Ala47] aFGF analog (with substitution at only position 47) suggested that the glycine-substituted amino acid 93 position of the bovine [Ala47,Gly93] aFGF analog might be within or near the region responsible for receptor binding. Although the receptor binding region in aFGF has not been determined, position 93 in aFGF corresponds to a region in bFGF which is reported to be within or near the receptor binding domain. Baird et al, Proc . Nat . Acad . Sci . USA, 85, 2324-2328 (1988) .
In addition, the bovine [Ala 7,Gly93] aFGF analog of the present invention, unlike the bovine [Ala47] analog, exhibited enhanced stability, maintaining its original itogenic activity in the absence of heparin over the course of 250 hours, while the bovine [Ala47] analog rapidly lost activity.
The bovine [Ala47,Gly93] aFGF analog was crystallized, and the resulting crystals examined by X-ray crystallography. The X-ray crystallographic data obtained from examination of these crystals supports the suggestion from the hydrophobic interaction chromatography data that residue 93 is exposed to solvent; i.e., that the glycine for histidine substitution at position 93 makes the molecule less hydrophilic. Detailed examination of the bovine [Ala47,Gly93] aFGF analog sequence around residue 93 revealed a clustering of approximately 8 amino acids with high loop-forming potentials in the region from about the glutamic acid residue at position 90 to about the tyrosine residue at position 97. The relative loop- forming potentials of amino acids have been reported, with glycine being identified as the amino acid residue having the highest loop-forming potential among all amino acids. Leszcynski et al . Thus, the glycine for histidine substitution is believed to stabilize the presumed loop, due to the much higher loop-forming potential of the glycine residue, compared with histidine.
Other aFGF analogs, in addition to the preferred [Gly93] analog specifically set forth herein, are contemplated by the present invention. These other analogs could easily be made by one skilled in the art by following the teachings provided herein. For
example, there are no fewer than fifteen amino acids reported to have higher loop-forming potential than histidine. Leszcynski et al . These amino acids are, in descending order of loop-forming potential, glycine, proline or tyrosine, aspartic acid or asparagine, serine, cysteine, glutamic acid, threonine, lysine, cystine, gluta ine, arginine, phenylalanine, and tryptophan. Substitution of any of these residues for the histidine residue at position 93 of naturally occurring aFGF could be expected to result in an aFGF analog of the present invention having an enhanced biological activity. Of course, it will be preferred to replace the histidine residue at position 93 with amino acids having the highest possible loop-forming potential, without creating any potential negative effects, such as the formation of undesired disulfide bonds through the insertion of additional cysteine or cystine residues. Thus other preferred amino acid substitutions at position 93 (i.e., in addition to glycine) are seen to include proline, tyrosine, aspartic acid, asparagine, serine, glutamic acid, threonine, lysine, glutamine, arginine, phenylalanine, and tryptophan.
The present invention also contemplates the substitution of an amino acid having high loop-forming potential for other amino acid residues within the amino acid 90 to 97 region of naturally occurring aFGF (i.e., amino acids 90-92 and 94-97) . The aFGF analogs of the present invention include, for example, aFGF analogs having the threonine residue at position 96 of naturally occurring aFGF replaced with glycine, proline or tyrosine, aspartic acid or asparagine, serine, or glutamic acid, in order of preference, although minimal enhancement of stability and/or biological activity
would be expected with the substitution of glutamic acid for threonine, due the similarity of loop-forming potential of these two amino acids. Likewise, the glutamic acid residues at positions 90 and 91 could be replaced with glycine, proline or tyrosine, aspartic acid or asparagine, or serine, again in order of preference.
The amino acid residues at positions 92, 94, 95, and 97 (asparagine, tyrosine, asparagine, and tyrosine, respectively) of naturally occurring aFGF have sufficiently high loop-forming potential that minimal benefits are envisioned to arise from substitution for these particular residues.
The aFGF analogs of the present invention are seen to encompass analogs of both human and bovine aFGF, as well as all forms of aFGF having the following amino acid sequence from amino acids 90 to 97 :
90 91 92 93 94 95 96 97 -Glu-Glu-Asn-His-Tyr-Asn-Thr-Tyr-
Both the human and bovine forms of aFGF are known, and have been identified as having the identical amino acid sequence (shown above) at positions 90 to 97. Moreover, there is approximately 92% sequence identity between human and bovine aFGF, and a 97% "similarity" (i.e., 5% of the total 8% changes between the two aFGF forms are "conservative") . Both the human and bovine forms of naturally occurring aFGF exhibit substantially the same in vitro mitogenic activity.
Because of their enhanced stability and biological activity in the absence of heparin, the novel
biologically active aFGF analogs of the present invention are particularly well suited for use in pharmaceutical formulations for the treatment by physicians and/or veterinarians of many types of wounds of mammalian species. The amount biologically active aFGF analog used in such treatments will, of course, depend upon the severity of the wound being treated, the route of administration chosen, and the specific activity or purity of the aFGF analog, and will be determined by the attending physician or veterinarian. The term "aFGF analog therapeutically effective" amount refers to the amount of aFGF analog determined to produce a therapeutic response in a mammal. Such therapeutically effective amounts are readily ascertained by one of ordinary skill in the art.
The aFGF analogs of the present invention may be administered by any route appropriate to the wound or condition being treated. Conditions which may be beneficially treated with therapeutic application(s) of the aFGF analog of the present invention include but are not limited to, the healing of surface wounds, bone healing, angiogenesis, nerve regeneration, and organ generation and/or regeneration.
The formulations of the present invention, both for veterinary and for human use, comprise a therapeutically effective amount of aFGF analog together with one or more pharmaceutically acceptable carriers therefore and optionally other therapeutic ingredients. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. The formulations may be conveniently presented in unit dosage form and may be prepared by any of the methods
well known in the art. All methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association the aFGF with liquid carriers or finely divided solid carriers or both.
The following examples are provided to aid in the understanding of the present invention, the true scope of which is set forth in the appended claims. It is understood that modifications can be made in the procedures set forth, without departing from the spirit of the invention.
Example 1
Production of the aFGF Analogs
Synthesis
A bovine aFGF analog according to the present invention was prepared and examined in the following examples. This analog, bovine [Ala47,Gly93] aFGF, was constructed to contain both a desired amino acid substitution (glycine for histidine at position 93) in the residue 90 to 97 region of the aFGF molecule and an additional amino acid substitution of alanine for the non-conserved cysteine residue at position 47, as shown in Fig. 1. A bovine [Ala47] aFGF analog, having only the amino acid substitution of alanine for cysteine was also prepared for use as a control for the desired bovine [Ala 7,Gly93] aFGF analog. Although these examples demonstrate a bovine aFGF analog of the present invention, the same results can be achieved for the
highly homologous human aFGF analogs. For example, the amino acid sequence of the corresponding human [Alai6,Gly93] aFGF analog of the present invention is displayed in Fig. 2.
A synthetic gene coding for the [Ala 7,Gly93] analog of bovine aFGF was assembled in two sections from a total of 28 component oligonucleotides. The amino acid sequence of Gimenez-Gallego et al was used as the basis for this gene, with codon choices selected to optimize expression of the analog in E. coli . Gimenez- Gallego et al, Science, 230, 1385-1388 (1985) . Section I was assembled from 16 oligonucleotides to yield a 287 nucleotide fragment which could be inserted into a plasmid vector at Xba I and Xho I restriction endonuclease sites. Section II was assembled from 12 oligonucleotides to give a 170 nucleotide fragment bounded by Xho I and Bam HI compatible ends. The two sections were inserted into the expression plasmid pCFM1156, which had been previously digested with Xba I and Bam HI in a 3-component ligation, yielding the complete aFGF gene under the control of the lambda pL promoter.
The plasmid pCFM1156 is prepared from the known plasmid pCFM836. The preparation of plasmid pCFM836 is described in U.S. Patent No. 4,710,473, the relevant portions of the specification, particularly examples 1 to 7, are hereby incorporated by reference. To prepare pCFM1156 from pCFM836, the two endogenous Nde I restriction sites are cut, the exposed ends are filled with T4 polymerase, and the filled ends are blunt-end ligated.
The resulting plasmid is then digested with Cla I and Kpn I and the excised DNA fragment is replaced with a DNA oligonucleotide of the following sequence:
5' CGATTTGATTCTAGAAGGAGGAATAACATATGGTTAACGCGTTGGAATTCGGTAC 3' 3' TAAACTAAGATCTTCCTCCTTATTGTATACCAATTGCGCAACCTTAAGC 5'
E. coli cells transformed with this plasmid were grown in a 16-liter fermentation vessel as described in Fox et al, J. Biol . Chem. , 263, 18452-18458 (1988).
The gene coding for the bovine [Gly93;,Ala47] aFGF was converted to the [Ala47] form using oligo site- directed mutagenesis. The aFGF gene was first transferred into the phage vector M13mpl8 and single- stranded DNA to serve as a template for the mutagenesis reaction was prepared. Approximately 0.5 μg of this DNA was mixed with 5 picomoles each of the mutagenic primer (5' GAAGAAAACCATTACAACAC 3') and the Ml3 universal primer used for DNA sequencing, heated to 65°C for 3 minutes, and allowed to slow cool. The annealed template-primer was mixed with ATP, a dNTP mixture, DNA polymerase I large fragment, and T4 DNA ligase, then incubated at 15°C for 4 hours. Aliquots of this reaction mixture were added to competent E. coli JMlOl cells and plated in 0.7% L-agar. The resulting plaques were replicated onto nitrocellulose filters, and the filters were hybridized with 32p-ιabeled mutagenic primer. DNA prepared from phage which hybridized was sequenced to verify successful completion of the desired mutagenesis event. The resultant gene was then transferred back to the pCFM1156 vector for expression of the recombinant protein.
Purification
Both the bovine [Gly93,Ala47] and [Ala 7] aFGF analogs were purified from the insoluble fraction obtained from centrifugation of mechanically lysed
E. coli cells expressing the recombinant protein. The pellet fraction was solubilized in 8 M urea, 0.1 M glycine, pH 2,5, and centrifuged to remove insoluble materials. The supernatant was loaded onto an S- Sepharose® (Pharmacia, Uppsala, Sweden) column equilibrated with 6 M urea, 10 mM glycine, pH 3.0, and washed with 6 M urea, 20 mM sodium citrate, pH 6.5. Proteins which bound to the column were eluted with a linear 0 to 0.5 M sodium chloride gradient in 20 mM sodium citrate, pH 6.5. The fractions containing the aFGF were pooled, diluted 20-fold with 20 mM sodium citrate,0.1 M ammonium sulfate, and centrifuged to remove any precipitate. The supernatant was mixed with one volume of 20 mM sodium citrate, 2 M ammonium sulfate, and loaded onto a phenyl-Sepharose® column equilibrated with 20 M sodium citrate, 1 M ammonium sulfate, pH 6.5. The bound proteins were eluted from the column with a linear descending gradient (1 M to 0 M) of ammonium sulfate. The aFGF-containing fractions were pooled and dialyzed against 20 mM sodium citrate, pH 6.5. This product was essentially homogeneous, as demonstrated by fact that no other bands in Coomassie blue appeared in the SDS gel, as shown in Fig. 4.
Example 2
Gel Filtration Chromatography
Gel filtration was performed at room temperature using a Superose®-12 column on a Pharmacia FPLC system
(Pharmacia, Uppsala, Sweden) . The column was run at 0.5 ml/min in 20 mM sodium citrate, 0.2 M sodium chloride, pH 6.5.
Gel filtration chromatography showed that the purified bovine [Ala47] and [Ala47,Gly93] aFGF analogs eluted as single peaks at an elution position identical to that of ribonuclease A (Mr = 13,"700). This indicated that both proteins are monomeric and have the same hydrodynamic radius, although there is a possibility that both forms of the protein interact with the column matrix and give a retarded elution from the column.
Example 3
Hydrophobic Interaction Chromatography
Hydrophobic interaction chromatography was performed at room temperature using a phenyl-Superose® column on a Pharmacia FPLC system. The sample, in 2 M ammonium sulfate, 20 mM sodium citrate, pH 6.5, was loaded onto the column which had been equilibrated with 2 M ammonium sulfate. After a 2 M sodium chloride wash, the remaining protein was eluted with an ammonium sulfate gradient descending from 2 M to 0 M, followed by a final wash with 20 mM sodium citrate, pH 6.5.
Because the elution position of a protein in hydrophobic interaction chromatography (HIC) is strongly dependent upon the exposure of hydrophobic regions in the folded state, this technique provides a sensitive probe of the conformationai homogeneity of similar proteins. Fig. 3 presents the elution profiles for the bovine [Ala47] and [Ala47,Gly93] aFGF analogs. The [Ala*47] aFGF showed a major peak eluting at 0.25 M
ammonium sulfate, while the [Ala47,Gly93] aFGF analog showed a single peak at 0.13 M ammonium sulfate, suggesting that both proteins exist primarily in a single distinct conformation. The elution at lower salt concentration by the [Ala47,Gly93] aFGF indicates that it is slightly more hydrophobic than the [Ala*47] form. This observation is consistent with the replacement of the histidine residue at position 93 by glycine if the conformation of the protein is such that this residue is exposed to the solvent. Alternatively, the change in this residue could induce an overall change in the conformation of the molecule to produce a more hydrophobic structure.
Example 4
Spectrpscopy
irc la pichro sm
Circular dichroic spectra were determined at room temperature on a Jasco Model J-500C spectrophotometer (Jasco, Tokyo, Japan) equipped with an Oki If 800 Model 30 computer (Oki, Tokyo, Japan) . Measurements were carried out at a band width of 1 nm using cuvettes of 1 and 0.02 cm for the near and far ultraviolet ranges, respectively. The data were expressed as the mean residue ellipticity, [θ] , calculated using the mean residue weight of 113 for both forms of aFGF.
Circular dichroism (CD) spectra of the bovine [Ala47,Gly93] and [Ala47] aFGF analogs were nearly identical in both the far and near ultraviolet regions, as shown in Figs. 4A and 4B, respectively. The CD of the analogs were also very similar to the spectrum
reported for human bFGF. (Arakawa, et al, BBRC, 161, 335-341 (1989) . The similarity of the spectra in the near ultraviolet region is consistent with similar tertiary structures for the FGFs.
Thermal Transition
The thermal transition of proteins was determined on a Response II spectrophotometer (Gilford, Medfield, Massachusetts) equipped with thermal programming and a thermal cuvette holder. Samples were heated at an increment of 0.l°C/min or 0.5°C/min and their absorbance monitored at 287 nm. Protein concentrations were determined spectrophotometrically using an extinction coefficient of 0.98 for bFGF and 1.04 for both bovine aFGF analogs at 280 nm for 0.1% protein.
Thermal denaturation of the aFGF analogs was examined in the presence and absence of heparin at both pH 6.5 and 7.0, 20 mM sodium citrate. In all cases, the proteins precipitated as the temperature was increased. The temperature at which the abrupt absorbance increase occurred was taken as the denaturation temperature. In the absence of heparin, this temperature was about 10°C higher for the bovine [Ala47,Gly 3] aFGF analog than for the bovine [Ala47] aFGF analog. Addition of either 1.4- fold or 8-fold (w/w) excess of heparin increased the denaturation temperature for both forms by 14-20°C, depending upon the rate of temperature increase used. The difference between the denaturation temperature of the two forms remained at about 10°C. There was no apparent effect of 1.4-fold or 8-fold (w/w) excess heparin on the CD spectra of either protein in the 240 to 340 nm range, although in the case of 8-fold excess
heparin, the aFGF spectrum in the 240-260 nm region was masked by the absorbance of the heparin itself.
Fourier-transform Infrared (FTIR) Spectroscopv
Fourier-transform infrared (FTIR) spectra were determined to further examine the similarity in conformation of both aFGFs. For FTIR spectroscopy, the proteins were thoroughly dialyzed against water. Each protein was prepared as a 2% solution in a 20 mM imidizole buffer made in D2O (Sigma Chemical Co., 99.9% isotopic purity) . Solutions were placed in IR cells with CaF2 windows and 100 μm spacers. For each spectrum, 1500 interferograms were collected and coded on a Nicolet 800 FTIR system equipped with a germanium- coated KBr beam splitter and a DTGS detector. The optical bench was continuously purged with dry nitrogen gas. Second derivative spectra were calculated as described in in Susi et al, Bioche . Biophyε. Res . Comm. , 115, 391-397 (1983) . A 9 point smoothing function was applied to the water vapor-subtracted spectra.
Fig. 5 shows the second derivative spectra of the [Ala47] and [Ala47,Gly93] bovine aFGF analogs in the amide I' (C=0 stretch in deuterated proteins) region. For polypeptides and proteins, the frequencies of the component bands in this region are related to secondary structure content. Surewicz et al , Biochem . Biophys . Acta, 952, 115-130 (1988) . The spectra show strong bands at 1630 and 1685 cm~l which are indicative of a significant amount of β-structures in the two proteins. A strong band near 1647 cm_l is indicative of the presence of irregular or disordered structures. The weaker peaks near 1666 and 1673 cirri arise from turn
structures. A small peak is present near 1651 cirri in the spectra of both proteins. Amide I* components near this frequency are typically assigned to α-helices. However, it was recently shown that this band may arise from loop structures. Wilder et al, Abstracts of the Fourth Symposium of the Protein Society, San Diego (1990) . As shown in Fig. 5, the highly resolved FTIR spectra, unlike CD, clearly demonstrate the presence of β-structures and turns, and the spectra for bovine [Ala47] aFGF analog and bovine [Ala 7,Gly 3] aFGF analog are nearly superimposable, again suggesting that these two proteins have similar conformation.
The second derivative spectra showed apparently no difference in conformation between the two aFGF analogs. However, it was evident that deuteration of exchangeable protons occurred faster for the bovine [Ala47] aFGF analog than for the [Ala47,Gly93] analog during equilibration of lyophilized protein with D2O solution. Since the two proteins have a similar conformation, the observed difference in H-D exchange rate cannot be explained from differences in the extent of exposure of exchangeable protons between them. It is more likely that the [Ala*47] aFGF analog has a more flexible structure, which render amide protons more accessible to the solvent.
Example 5
Heparin Chromatography
Heparin-Sepharose® (Pharmacia) was packed into a 1 x 8 cm column and equilibrated with 10 mM Tris-HCl, pH 7.2. The column was loaded, washed with 10 mM Tris-HCl, pH 7.2 and eluted with a linear gradient from 0 to 2.8 M
sodium chloride in the same buffer at a flow rate of 0.5 ml/min using a Pharmacia FPLC system.
Acidic and basic FGF are distinguished by their avid binding to heparin and heparin-like molecules. Both the bovine [Ala47,Gly93] and [Ala47] aFGF analogs showed a single peak eluting at 1.54 M sodium chloride in 10 mM Tris-HCl, pH 7.2.
Example 6
Biological Activity of aFGF Analogs
In Vitro Bioassavs
The mitogenic activity on NIH 3T3 cells of the aFGF analogs from the previous examples was determined as described below. In addition, a human [Ser70,Ser88] bFGF analog, prepared as described in published PCT Patent Application No. 88/04189, was also examined in the bioactivity assays, alongside the aFGF analogs.
NIH 3T3 cells were obtained from ATCC. The cells were grown in DME supplemented with 10% calf serum, 10 units/ml penicillin, 2 mM glutamine and 10 units/ml streptomycin. Cells were passaged at a ratio of 1:40 two times per week. On day 1 of the assay, subconfluent cultures were trypsin dispersed and plated into 24-well plates at a concentration of 20,000 cells/ml, 1 ml per well in the above media. On day 5, the media was replaced with 1 ml/well DMEM without serum but containing penicillin, streptomycin, and glutamine at the above concentrations. On day 6, experimental samples were added to the media in volumes no greater than 100 μl. Eighteen hours later, cells were pulsed
for 1 hour with 1 ml of the above media containing 2 10 μCi of tritiated thymidine at 37°C. After the pulse, cells were washed once with media, then 250 mM sucrose, 10 mM sodium phosphate, 1 mM EDTA, pH 8 was added and the plates incubated at 37°C for 10 minutes to release the cells. Cells were harvested on a Skatron harvester. (Skatron, Inc., Sterling, Virginia.) Filters were dried, placed in scintillation fluid, and counted in a Beckman scintillation counter. (Beckman Instruments, Inc., Fullerton, California.)
The mitogenic activity of the bovine [Ala47,Gly93] and [Ala47] aFGF analogs on NIH 3T3 cells was examined as shown in Fig. 6. In the absence of heparin, the [Ala47] aFGF analog produced a dose dependent stimulation of 3κ-thymidine uptake in the range of 1 to 100 ng/ml, with half-maximal stimulation of 25 ng/ml. Under the same assay conditions, the [Ala 7,Gly93] aFGF analog was able to produce the same mitogenic effect at a much lower protein concentration, the half-maximal dose being about 1 ng/ml. Recombinant bFGF was 4-5 times more potent than the [Ala47,Gly93] aFGF, with a half-maximal dose of 220 pg/ l. When 4.5 μg/ml heparin was added to both analogs, their in vitro activity was increased with the [Ala47,Gly93] aFGF analog remaining more potent. In the presence of 45 μg/ml heparin, the activities were enhanced such that the dose response of all three molecules were nearly identical, with a half- maximal dose of 90 pg/ml.
The stability of the aFGF analogs, as determined by retention of their respective mitogenic activity, was examined by incubation of a 0.1 mg/ml solution of each FGF analog in 20 mM sodium citrate, pH 7 at 37°C, both in the presence and absence of 1 mg/ml heparin. In the
absence of heparin, the bovine [Ala47] aFGF analog rapidly lost activity, with a half-life of about 13 hours, as shown in Fig. 7. However, in the presence of heparin, bovine [Ala47] aFGF lost no biological activity over the 250 hour course of the experiment. In contrast, neither bovine [Ala47,Gly 3] aFGF analog nor the human [Ser70,Ser88] bFGF analog exhibited any loss of activity over the 250 hours, whether or not heparin was present.
Example 7
Crystallography
Crystals of bovine [Ala47,Gly93] aFGF analog were grown by vapor diffusion against 0.2 M NH4SO4, 2 M NaCl, 0.099 M sodium citrate, and 0.02 M sodium potassium phosphate, pH 5.6. The protein droplet contained equal volumes of the reservoir solution and a 10 mg/ml protein solution. The crystals were trigonal (space group
P3_21, a = "78.6 A, c = 115.9 A) and diffracted to 2.5 A resolution. Intensity data were collected with a Siemens (Madison, Wisconsin) multiwire area detector mounted on an 18 kw rotating anode generator. The Siemens suite of processing programs was used for data reduction. Multiple isomorphous replacement (mir) phases were calculated to 3 A resolution from two derivatives, with a figure of merit of 0.68. After solvent flattening, regions corresponding to two independent aFGF molecules in the asymmetric unit were identified. The general non-crystallographic symmetry relationships between these molecules were determined from rotation function, real-space translation function, and density correlation studies. A molecular envelope was defined around an averaged aFGF molecule with a
modified B.C. Wang algorithm. The phases were iteratively refined by molecular averaging and solvent flattening.
Initial maps revealed extended regions of β sheet structure that were truncated at the loops, due to a small molecular envelope, as shown in Fig. 8. The final map for model building was calculated with ir phases (from heavy atom parameters re-refined against averaged phases, as described in Rould et al, Science, 246, 1135- 1142 (1989) ) , and iteratively averaged with a molecular envelope generated by placing 6 A spheres about the atomic positions in the initial model. Averaging at 3 A resolution converged to a final R-factor of 17.8 % between the observed structure factors, and structure factors calculated from the averaged and solvent flattening map. The graphic program TOM/FRODO, implemented for a Silicon Graphics 4D80 by C Cambillau, was used to build residues 10 to 136 of the aFGF sequence into an averaged electron density map.
The crystallography results supported our hypothesis that the 90-97 region is involved in a loop structure. If this region is, in fact, involved in receptor binding as suggested by Baird et al, any amino acid substitution which stabilizes the loop may stabilize and/or enhance the biological activity of the molecule. This is presumably the mechanism for the observed activity enhancement attained with the bovine [Ala ,Gl 93] aFGF.
Claims (33)
1. An analog of acidic fibroblast growth factor wherein said analog has an enhanced biological activity of at least about ten times that of naturally occurring acidic fibroblast growth factor in the absence of hepari .
2. An analog of acidic fibroblast growth factor wherein at least one amino acid in the region of amino acids 90 to 97 of said naturally occurring acidic fibroblast growth factor is replaced by a residue of a different amino acid having a higher loop-forming potential.
3. The analog of claim 2 wherein said replaced amino acid is selected from the group consisting of amino acids 90, 91, 93, and 96.
4. The analog of claim 3 wherein said replaced amino acid is amino acid 90.
5. The analog of claim 4 wherein said amino acid having a higher loop-forming potential is selected from the group consisting of glycine, proline, tyrosine, aspartic acid, asparagine and serine.
6. The analog of claim 4 wherein said amino acid having a higher loop-forming potential is glycine.
7. The analog of claim 3 wherein said replaced amino acid is amino acid 91.
8. The analog of claim 7 wherein said amino acid having a higher loop-forming potential is selected from the group consisting of glycine, proline, tyrosine, aspartic acid, asparagine and serine.
9. The analog of claim 8 wherein said amino acid having a higher loop-forming potential is glycine.
10. The analog of claim 3 wherein said replaced amino acid is amino acid 96.
11. The analog of claim 10 wherein said amino acid having a higher loop-forming potential is selected from the group consisting of glycine, proline, tyrosine, aspartic acid, asparagine, seririe, and glutamic acid.
12. The analog of claim 11 wherein said amino acid having a higher loop-forming potential is glycine.
13. The analog of claim 3 wherein said replaced amino acid is amino acid 93.
14. The analog of claim 13 wherein said amino acid having a higher loop-forming potential is selected from the group consisting of glycine, proline, tyrosine, aspartic acid, asparagine, serine, glutamic acid, threonine, lysine, glutamine, arginine, phenylalanine, and tryptophan.
15. The analog of claim 14 wherein said amino acid having a higher loop-forming potential is glycine.
16. The analog of claim 15 having the amino acid sequence set forth in Fig. 1.
17. The analog of claim 15 having the amino acid sequence set forth in Fig. 2.
18. The analog of claim 3 wherein at least one terminal amino acid residue is deleted while said analog substantially retains said enhanced biological activity.
19. The analog of claim 3 wherein at least one cysteine residue of said naturally occurring acidic fibroblast growth factor is replaced by a residue of a neutral amino acid.
20. The analog of claim 19 wherein said analog is an analog of bovine acidic fibroblast growth factor and said cysteine residue is the cysteine residue at position 47 of said naturally occurring acidic fibroblast growth factor.
21. The analog of claim 19 wherein said analog is an analog of human acidic fibroblast growth factor and said cysteine residue is the cysteine residue at position 16 of said naturally occurring acidic fibroblast growth factor.
22. A DNA sequence encoding for procaryotic or eucaryotic expression of an analog of an acidic fibroblast growth factor of claim 3.
23. The DNA sequence of claim 22 wherein said analog of an acidic fibroblast growth factor is the analog of claim 15.
24. The DNA sequence of claim 20 wherein said analog of an acidic fibroblast growth factor is the analog of claim 16.
25. The DNA sequence of claim 20 wherein said analog of an acidic fibroblast growth factor is the analog of claim 17.
26. A pharmaceutical composition comprising a therapeutically effective amount of an acidic fibroblast growth factor analog according to claim 1 and one or more pharmaceutically acceptable adjuvants.
27. The pharmaceutical composition of claim 26 wherein said acidic fibroblast growth factor analog is the analog of claim 3.
28. The pharmaceutical composition of claim 26 wherein said acidic fibroblast growth factor analog is the analog of claim 15.
29. The pharmaceutical composition of claim 26 wherein said acidic fibroblast growth factor analog is the analog of claim 16.
30. A method for treating a wound comprising administering to said wound a therapeutically effective amount of an acidic fibroblast growth factor analog according to claim 1.
31. The method of claim 30 wherein said acidic fibroblast growth factor analog is the analog of claim 3.
32. The method of claim 30 wherein said acidic fibroblast growth factor analog is the analog of claim 15.
33. The method of claim 30 wherein said acidic fibroblast growth factor analog is the analog of claim 16.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63245690A | 1990-12-18 | 1990-12-18 | |
US632456 | 1990-12-18 | ||
PCT/US1991/009441 WO1992011360A1 (en) | 1990-12-18 | 1991-12-17 | Analogs of acidic fibroblast growth factor having enhanced stability and biological activity |
Publications (2)
Publication Number | Publication Date |
---|---|
AU9152491A AU9152491A (en) | 1992-07-22 |
AU663067B2 true AU663067B2 (en) | 1995-09-28 |
Family
ID=24535601
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU91524/91A Ceased AU663067B2 (en) | 1990-12-18 | 1991-12-17 | Analogs of acidic fibroblast growth factor having enhanced stability and biological activity |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0575339A4 (en) |
JP (1) | JPH06503962A (en) |
KR (1) | KR930703439A (en) |
AU (1) | AU663067B2 (en) |
CA (1) | CA2098484A1 (en) |
IE (1) | IE914393A1 (en) |
IL (1) | IL100418A0 (en) |
NZ (1) | NZ241021A (en) |
WO (1) | WO1992011360A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2717495B1 (en) * | 1994-03-18 | 1996-04-12 | Rhone Poulenc Rorer Sa | Recombinant viruses, preparation and use in gene therapy. |
DE69530599T2 (en) * | 1994-10-13 | 2003-11-13 | Amgen Inc., Thousand Oaks | METHOD FOR CLEANING KERATINOCYTE GROWTH FACTORS |
SK43297A3 (en) * | 1994-10-13 | 1998-01-14 | Amgen Inc | Analogs of acidic fibroblast growth factor having enhanced stability and biological activity |
JP2733207B2 (en) * | 1995-05-18 | 1998-03-30 | 工業技術院長 | Pharmaceutical composition containing fibroblast growth factor chimeric protein |
US6743422B1 (en) | 1996-10-15 | 2004-06-01 | Amgen, Inc. | Keratinocyte growth factor-2 products |
AU782819B2 (en) * | 1999-04-15 | 2005-09-01 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | Angiogenic growth factors for treatment of peripheral neuropathy |
US7125856B1 (en) | 1999-04-15 | 2006-10-24 | St. Elizabeth's Medical Center Of Boston, Inc. | Angiogenic growth factors for treatment of peripheral neuropathy |
US20070134204A1 (en) * | 2005-12-09 | 2007-06-14 | Henrich Cheng | Method for treating nerve injury and vector construct for the same |
WO2009048119A1 (en) * | 2007-10-12 | 2009-04-16 | National Institute Of Advanced Industrial Science And Technology | Medicinal composition containing highly functionalized chimeric protein |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0391052A2 (en) * | 1989-03-18 | 1990-10-10 | Sms Schloemann-Siemag Aktiengesellschaft | Continuous casting machine for casting of profiled girders |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62270597A (en) * | 1986-03-07 | 1987-11-24 | プレジデント・アンド・フエロウズ・オブ・ハ−バ−ド・カレジ | Human kind 1 heparin bondable growth factor |
AU629176B2 (en) * | 1987-07-07 | 1992-10-01 | Scios Nova Inc. | Recombinant fibroblast growth factors |
NZ226543A (en) * | 1987-10-22 | 1992-02-25 | Merck & Co Inc | Recombinant mutant acidic fibroblast growth factor |
-
1991
- 1991-12-17 CA CA002098484A patent/CA2098484A1/en not_active Abandoned
- 1991-12-17 WO PCT/US1991/009441 patent/WO1992011360A1/en not_active Application Discontinuation
- 1991-12-17 NZ NZ241021A patent/NZ241021A/en unknown
- 1991-12-17 AU AU91524/91A patent/AU663067B2/en not_active Ceased
- 1991-12-17 JP JP4503720A patent/JPH06503962A/en active Pending
- 1991-12-17 IE IE439391A patent/IE914393A1/en not_active Application Discontinuation
- 1991-12-18 IL IL100418A patent/IL100418A0/en unknown
-
1992
- 1992-07-17 EP EP92902895A patent/EP0575339A4/en not_active Withdrawn
-
1993
- 1993-06-17 KR KR1019930701853A patent/KR930703439A/en not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0391052A2 (en) * | 1989-03-18 | 1990-10-10 | Sms Schloemann-Siemag Aktiengesellschaft | Continuous casting machine for casting of profiled girders |
Also Published As
Publication number | Publication date |
---|---|
AU9152491A (en) | 1992-07-22 |
EP0575339A4 (en) | 1995-04-05 |
WO1992011360A1 (en) | 1992-07-09 |
NZ241021A (en) | 1993-12-23 |
IL100418A0 (en) | 1992-09-06 |
IE914393A1 (en) | 1992-07-01 |
CA2098484A1 (en) | 1992-06-19 |
KR930703439A (en) | 1993-11-30 |
EP0575339A1 (en) | 1993-12-29 |
JPH06503962A (en) | 1994-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU638402B2 (en) | Analogs of fibroblast growth factor | |
AU663298B2 (en) | Heparin binding mitogen with homology to epidermal growth factor (EGF) | |
US5461034A (en) | Osteogenic growth polypeptides identified from regenerating bone marrow | |
CZ297329B6 (en) | Analog of native keratinocyte growth factor covalently attached to polyethylene glycol or related water-soluble organic polymer, its use and in vitro method of stimulating non-fibroblast epithelial cell proliferation | |
US5223483A (en) | Cysteine-modified acidic fibroblast growth factor | |
CA2201944C (en) | Analogs of keratinocyte growth factor having enhanced temperature stability | |
AU663067B2 (en) | Analogs of acidic fibroblast growth factor having enhanced stability and biological activity | |
DE69530404T2 (en) | KERATINOCYTE GROWTH FACTOR ANALOGS | |
EP0319052B1 (en) | Mutant acidic fibroblast growth factor | |
Arakawa et al. | Production and characterization of an analog of acidic fibroblast growth factor with enhanced stability and biological activity | |
DE69933057T2 (en) | ANALOGS OF THE HUMAN BASIC FIBROBLAST GROWTH FACTOR | |
US5409897A (en) | Cysteine-modified acidic fibroblast growth factor and methods of use | |
EP0384731A2 (en) | Osteogenic growth polypeptides identified from regenerating bone marrow | |
PL209955B1 (en) | Muteins of placental growth factor type 1, preparation method and application thereof | |
MXPA97002475A (en) | Analogues of the fibroblast acid growth factor that have stability and biological acticity improves | |
EP0494664A1 (en) | Human bFGF derivatives, their analogs and process for their production | |
CA1340639C (en) | Mutant acidic fibroblast growth factor | |
CA2079291A1 (en) | Activities of heparin binding neurite-outgrowth promoting factor |